ISRCTN60385283进行中（未招募）2 期
A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis
Redx Pharma (United Kingdom)0 个研究点目标入组 64 人开始时间: 2022年5月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Ability to provide signed and dated informed consent
- •2. Aged =40 to 80 years at the time of signing the informed consent
- •3. Diagnosis of IPF within 5 years of Screening based on the modified IPF guidelines for diagnosis and management of IPF and confirmed on independent central imaging review
- •4. Combination of HRCT pattern, as assessed by central reviewers, consistent with diagnosis of IPF
- •5. FVC % predicted =50% predicted of normal at Screening, with no clinically significant deterioration between the Screening Visit and randomisation, as determined by the Investigator
- •6. DLco (Hb-adjusted) at screening =30%
- •7. In the main study, participants receiving treatment for IPF with nintedanib or pirfenidone are allowed if on treatment for at least 3 months and on a stable dose for at least 4 weeks prior to Screening and during Screening
- •8. In patients who are not on any treatment for IPF but have previously received nintedanib or pirfenidone, there needs to be a washout period =4 weeks prior to Screening
- •9. No clinically significant history of previous allergy/ sensitivity to RXC007 or any of the excipients contained within the Investigational Medicinal Product (IMP)
- •10. Blood cell parameters within the following limits:
- •10.1. Haemoglobin >10 g/dL
- •10.2. WBC count >3.00 × 10³/µL
- •10.3. Neutrophils >1.50 × 10³/µL
- •10.4. Platelets >80 × 10³/µL
- •11. Alanine transaminase (ALT) and aspartate transaminase (AST) <2x upper limit of normal (ULN). Total bilirubin <1.5 ULN.
- •12. Negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg) and hepatitis C virus antibody (HCV Ab) test results at Screening.
- •13. No clinically significant abnormalities in 12-lead ECG determined within 28 days before first dose of IMP including a QTcF interval >470 ms.
- •14. No clinically significant abnormalities, in the opinion of the investigator, in vital signs (e.g., blood pressure, pulse rate, respiration rate, oral temperature) within 28 days before first dose of IMP.
- •15. Patients must be willing to comply with institutional COVID-19 testing policy.
- •16. Female patients must be surgically sterile, post-menopausal (minimum 1 year without menses), or agree to use two or more of the following forms of highly effective contraception with all male sexual partners from the time of signing the Patient Informed Consent Document (PICD) until 3 months after the last dose of study medication: hormonal (i.e., oral, transdermal, implant, or injection); intrauterine device (IUD), Intrauterine system (IUS) (e.g., Mirena), or bilateral tubal occlusion; vasectomised partner (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate); or abstinence.
- •17. Men must use a condom (with spermicide) during the study, and for 3 months after the last dose of study drug, with all sexual partners. Men must not donate sperm for 3 months after the last dose of study drug.
- •Additional Inclusion Criteria for the Translational Science Sub Study only:
- •18. Patients must be considered fit to undergo two bronchoscopies, in the opinion of the Investigator.
排除标准
- •1. Currently receiving or planning to initiate treatment for IPF with agents not approved for that indication
- •2. FEV1/FVC ratio <0.7 at Screening, pre-bronchodilator use
- •3. Lower respiratory tract infection requiring antibiotics within 4 weeks of Screening or during Screening
- •4. The extent of emphysema in the lungs exceeds fibrosis, based on central review of HRCT scans
- •5. Need for continuous oxygen supplementation, defined as >15 hours/day
- •6. Acute IPF exacerbation within 6 months of Screening or during Screening
- •7. History of ongoing malignant disease, including solid tumours and hematologic malignancies, with the exception of basal cell carcinoma, squamous-cell carcinoma, and carcinoma in situ of the cervix that have been completely excised and considered cured >2 years prior to Screening
- •8. Significant cardiac disease (e.g., New York Heart Association Class 3 or 4; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty or coronary artery bypass graft within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias; or pulmonary hypertension requiring pharmacologic treatment)
- •9. Clinical diagnosis of any connective-tissue disease (including, but not limited to, scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis) or a diagnosis of interstitial pneumonia with autoimmune features as determined by the Investigator
- •applying the recent ERS/ATS research statement. Note: Serological testing is not needed if not clinically indicated
- •10. Creatinine clearance <60 mL/min according to Cockcroft Gault equation
- •11. A clinically significant history of GI disorder likely to influence IMP absorption
- •12. A clinically significant history of infection in the last 3 months
- •13. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction
- •14. A clinically significant history of drug or alcohol abuse within the past 3 months prior to Screening
- •15. Disease other than IPF with a life expectancy of less than 12 weeks
- •16. Inability to communicate well with the Investigators (i.e., language problem, poor mental development, or impaired cerebral function)
- •17. Participation in a New chemical entity (NCE) clinical study within the previous 3 months or five half-lives, whichever is longer, or a marketed drug clinical study within the 30 days or five half-lives, whichever is longer
- •18. Female who is pregnant or breastfeeding
- •19. Patients who are currently receiving prohibited medications and are unable to stop
- •20. Patients who are currently receiving steroids or formal anticoagulants (antiplatelet agents are permitted) and are unable to stop
- •21. Participants who have received a COVID-19 vaccine injection within 72 hours prior to the first dose of IMP
- •Additional exclusion criteria for the Translational Science Sub Study:
- •22. Participants with any contra-indication to bronchoscopy and alveolar lavage including tracheal stenosis, pulmonary hypertension, severe hypoxia, or hypercapnia
- •23. Patients in the sub study are not permitted to receive nintedanib or pirfenidone within 3 weeks of randomisation and throughout the Treatment period
研究者
相似试验
进行中（未招募）
1 期
A study to investigate if use of FOL-005 can increase hair growth.EUCTR2017-003809-17-DEFollicum AB60
已完成
不适用
Assessing the clinical benefit of food supplement, Genecol®, in subjects with joint pain at the lower, upper limbs or at the lumbar spineJoint painMusculoskeletal DiseasesOther joint disorders, not elsewhere classifiedISRCTN76960238utraveris (France)200
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled Phase IIIb Study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablets.EUCTR2006-005263-26-ESALK-Abelló, S.A.
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of asthma symptoms caused by respiratory virusesEUCTR2009-017480-42-GBSynairgen Research Ltd147
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral infection for the prevention or attenuation of COPD symptoms caused by respiratory viruses - Phase II: Inhaled SNG001 in COPD subjectsEUCTR2010-022110-29-GBSynairgen Research Limited166